The objectives of this phase I study are:~to evaluate the safety profile of the AdimrSC-2f vaccine, and~to assess the immunogenicity of the AdimrSC-2f vaccine.
This study aims to evaluate the safety and immunogenicity of the preventative vaccine, AdimrSC-2f, in healthy volunteers aged from 20 to 60 years old.